Chi-Ting Huang, Ph.D. is a Senior Director of CMC at Invetx and has almost 20 years of experience in biotechnology. She has held positions of increasing responsibility at several biotech companies including Surface Oncology, Momenta Pharmaceuticals, Acceleron Pharma, Immunogen Inc., and Genetics Institute/Wyeth Biopharma. She has built and lead Analytical Development and CMC teams for the development of protein and novel biotherapeutics (e.g. biosimilars, antibody-drug conjugates, highly glycosylated fusion proteins, TGF-beta proteins). Her experience spans the initial IND for luspatercept as well as characterization for the commercialization of the Infuseā¢Bone Graft. Dr. Huang received a Ph.D. in Biochemistry from the University of Minnesota and a B.S. in Chemical Engineering from the University of Illinois.